CRISPR Therapeutics AG (CRSP) Stock Rating

Crispr Therapeutics is a gene-editing company developing therapeutics based on Crispr/Cas9, a technology (clustered regularly interspaced short palindromic repeats and Crispr-associated protein 9) for precisely altering specific genomic DNA sequences. The company applies this technology to genetically defined diseases. Its first approved drug, Casgevy, was developed with Vertex Pharmaceuticals and treats sickle-cell disease and transfusion-dependent beta-thalassemia.